









Markets
/
Stocks
/
nasdaq-moln
/

Molecular Partners AG

MOLN



View Detailed Chart

4.460USD

+0.070+1.59%

Market hours （ET）Quotes delayed by 15 min

166.80MMarket Cap

LossP/E TTM



Molecular Partners AG

4.460

+0.070+1.59%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

+1.59%

5 Days

+3.12%

1 Month

+10.40%

6 Months

+14.65%

Year to Date

-6.07%

1 Year

-12.20%

View Detailed Chart

TradingKey Stock Score of Molecular Partners AG

Currency: USD Updated: 2025-12-19

Key Insights

Molecular Partners AG's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 97/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.54.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Molecular Partners AG's Score

Industry at a Glance

Industry Ranking

97 / 404

Overall Ranking

213 / 4582

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

13.541

Target Price

+222.11%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Molecular Partners AG Highlights

StrengthsRisks

Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

Growing

The company is in a growing phase, with the latest annual income totaling USD 5.63M.

Fairly Valued

The company’s latest PE is -2.17, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 3.59M shares, decreasing 0.65% quarter-over-quarter.